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Hyaluronidase and Hyaluronan Oligosaccharides Promote
Neurological Recovery after Intraventricular Hemorrhage
Govindaiah Vinukonda,1 Preeti Dohare,1 X Arslan Arshad,1 Muhammad T. Zia,1 Sanjeet Panda,1 Ritesh Korumilli,1
Robert Kayton,3 Vincent C. Hascall,4 Mark E. Lauer,4*† and Praveen Ballabh1,2*
Departments of 1Pediatrics and 2Cell Biology and Anatomy, Regional Neonatal Center, Maria Fareri Children’s Hospital at Westchester Medical Center, New
York Medical College, Valhalla, New York 10595, 3Department of Physiology and Pharmacology, Oregon Health & Science University, Portland, Oregon
97239, and 4Department of Biomedical Engineering, Cleveland Clinic, Cleveland, Ohio 44195
Intraventricular hemorrhage (IVH) in premature infants results in inflammation, arrested oligodendrocyte progenitor cell (OPC) mat-
uration, and reduced myelination of the white matter. Hyaluronan (HA) inhibits OPC maturation and complexes with the heavy chain
(HC) of glycoprotein inter--inhibitor to form pathological HA (HC–HA complex), which exacerbates inflammation. Therefore, we
hypothesized that IVH would result in accumulation of HA, and that either degradation of HA by hyaluronidase treatment or elimination
of HCs from pathological HA by HA oligosaccharide administration would restore OPC maturation, myelination, and neurological
function in survivors with IVH. To test these hypotheses, we used the preterm rabbit model of glycerol-induced IVH and analyzed autopsy
samples from premature infants. We found that total HA levels were comparable in both preterm rabbit pups and human infants with and
without IVH, but HA receptors—CD44, TLR2, TLR4 —were elevated in the forebrain of both humans and rabbits with IVH. Hyaluroni-
dase treatment of rabbits with IVH reduced CD44 and TLR4 expression, proinflammatory cytokine levels, and microglia infiltration. It
also promoted OPC maturation, myelination, and neurological recovery. HC–HA and tumor necrosis factor-stimulated gene-6 were
elevated in newborns with IVH; and depletion of HC–HA levels by HA oligosaccharide treatment reduced inflammation and enhanced
myelination and neurological recovery in rabbits with IVH. Hence, hyaluronidase or HA oligosaccharide treatment represses inflamma-
tion, promotes OPC maturation, and restores myelination and neurological function in rabbits with IVH. These therapeutic strategies
might improve the neurological outcome of premature infants with IVH.
Key words: hyaluronan; hyaluronan oligosaccharides; hyaluronidase; microglia; myelination; oligodendrocyte
Introduction
Intraventricular hemorrhage (IVH) remains a major cause of
neonatal white matter (WM) injury in premature infants. No
therapeutic strategy exists to prevent cerebral palsy and cognitive
deficits in the survivors of IVH. In human premature infants,
white matter lesions display an abundance of hyaluronan (HA),
overexpression of HA receptor CD44, arrested maturation of oli-
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Significance Statement
Approximately 12,000 premature infants develop IVH every year in the United States, and a large number of survivors with IVH
develop cerebral palsy and cognitive deficits. The onset of IVH induces inflammation of the periventricular white matter, which
results in arrested maturation of OPCs and myelination failure. HA is a major component of the extracellular matrix of the brain,
which regulates inflammation through CD44 and TLR2/4 receptors. Here, we show two mechanism-based strategies that effec-
tively enhanced myelination and neurological recovery in preterm rabbit model of IVH. First, degrading HA by hyaluronidase
treatment reduced CD44 and TLR4 expression, proinflammatory cytokines, and microglial infiltration, as well as promoted
oligodendrocyte maturation and myelination. Second, intraventricular injection of HA oligosaccharide reduced inflammation
and enhanced myelination, conceivably by depleting HC–HA levels.
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godendrocyte precursor cells (OPCs), and reduced myelination
(Buser et al., 2012). HA inhibits OPC maturation and myelina-
tion in animal models of demyelinating brain lesions and in cell
culture experiments (Preston et al., 2013). Therefore, we asked
whether the development of IVH in preterm infants would result
in accumulation of a specific modification of HA in the periven-
tricular white matter and whether breakdown of HA by hyal-
uronidase treatment or reversing specific modification of HA
would restore myelination and neurological function in infants
with IVH.
HA is a negatively charged glycosaminoglycan polymer, which
accumulates in the white matter lesions of premature infants,
adult stroke, multiple sclerosis, traumatic spinal cord injury, and
vanishing white matter disease (Struve et al., 2005; Al’Qteishat et
al., 2006; Cargill et al., 2012). HA fragments of low molecular
weight (LMW) and high molecular weight (HMW) exhibit a wide
range of biological functions. HMW species can be immunosup-
pressive, antiangiogenic, and protective, whereas LMW HA frag-
ments can be proinflammatory and angiogenic (Stern et al.,
2006). Nonetheless, HMW HA (0.9  10 6 Da) inhibits remy-
elination in a mouse model of lysolecithin-induced white matter
demyelination, but not LWM HA (3  10 5 Da) (Back et al.,
2005). HA interacts with CD44 and TLR2/4 receptors, which are
predominantly expressed on astrocytes and OPCs (Sloane et al.,
2010; Buser et al., 2012). TLR2/4 receptors are activated in cere-
bral ischemia, trauma, hemorrhage, and infection (Konat et al.,
2006; Fischer and Ehlers, 2008; Rivest, 2009), and inhibition of
TLR2/4 offers neuroprotection in several adult rodent models of
brain injury (Lehnardt et al., 2007; Tang et al., 2007). CD44 levels
are chronically elevated in demyelinating lesions of multiple scle-
rosis, and antagonizing CD44 promotes remyelination and neu-
rological recovery (Tuohy et al., 2004; Guan et al., 2011). Hence,
specific fragments of HA can induce white matter injury, which
can potentially be reversed by degrading HA or by blocking its
binding receptors.
IVH in premature newborns induces inflammation, and
COX2 or TNF inhibition alleviates inflammation and promotes
myelination along with neurological recovery in rabbits with IVH
(Vinukonda et al., 2010). Proinflammatory cytokines have been
shown to induce expression of tumor necrosis factor-stimulated
gene-6 (TSG-6) in inflammatory disorders such as rheumatoid
arthritis and sepsis (Milner and Day, 2003). TSG-6 catalyzes the
covalent transfer of heavy chains (HCs) from inter- trypsin in-
hibitor (II) proteoglycan to HA to form HC–HA complexes
(Milner and Day, 2003). HC–HA complexes exhibit proinflam-
matory activity by promoting adhesion of leukocytes to HA ma-
trices and by extravasation of leukocytes into the interstitial
spaces (Zhuo et al., 2006). HA oligosaccharides of 8 –21 mono-
saccharides (1.5 kDa) have been used to remove the HCs from
HC–HA complexes, thereby reducing the concentration of path-
ological HC–HA (Lauer et al., 2013b). HA oligosaccharides also
impede HA–CD44 interaction by inducing CD44 receptor cleav-
age and by competitive binding to CD44 (Sugahara et al., 2003;
Teriete et al., 2004). Indeed, HA oligosaccharide treatment offers
neuroprotection in a mouse model of experimental allergic en-
cephalitis (Winkler et al., 2013).
Although HA and myelination have been studied in adult
animal models of demyelination, the dynamics of HA synthesis
and degradation and the effect of HA on myelination have not
been evaluated in a developmental model of brain injury in pre-
mature newborns. Therefore, we hypothesized that IVH would
result in the accumulation of specific fragments of HA and that
degradation of HA by hyaluronidase treatment might reduce in-
flammation and restore OPC maturation and myelination in pre-
term survivors of IVH. We also postulated that TSG-6 activity is
increased in IVH, resulting in increased production of patholog-
ical HC–HA, and that eliminating HCs from HC–HA com-
plexes by treatment with HA oligosaccharides might reduce
cerebral inflammation and enhance myelination as well as
clinical recovery.
Materials and Methods
Animals. This study was approved by the Institutional Animal Care and
Use Committee of the New York Medical College (Valhalla, NY). We
used our well-established preterm rabbit model of glycerol-induced IVH
for the study (Chua et al., 2009; Vinukonda et al., 2010; Dummula et al.,
2011). Briefly, we purchased timed-pregnant New Zealand white rabbits
from Charles River Laboratories. We performed Cesarean sections to
deliver the premature pups at embryonic day 29 (E29; full term, 32 d).
Newborn pups were reared in an infant incubator at a temperature of
35°C. We used puppy formula (Zoologic) to gavage feed the pups in a
volume of 2 ml every 12 h (100 ml/kg/d) for the first 2 d, and feeds were
advanced to 125,150, 200, 250 and 280 ml/kg at postnatal day 3 (P3), P5,
P7, P10, and P14, respectively. We treated rabbit pups of either sex with
50% intraperitoneal glycerol (6.5 gm/kg) at 3 h of age to induce IVH (Fig.
1). Severity of IVH was determined by measuring ventricle volume by
head ultrasound at 24 h age using an Acuson Sequoia C256 (Siemens)
ultrasound machine. Pups were classified as moderate (30 –150 mm 3)
and severe (151–250 mm 3) IVH, based on ventricular volume. Ventric-
ular volume of 30 mm 3 indicated microscopic or no IVH.
Hyaluronidase and HA oligosaccharide (10 monosaccharide unit) treat-
ment. The rabbit pups with IVH were sequentially treated with either 20
l of hyaluronidase from Streptomyces hyalurolyticus (hyaluronidase, 1
U/l; Sigma) or vehicle (saline) intracerebroventricularly at days 2, 4,
and 6. Briefly, the pups were mounted on a rabbit pup restrainer after
anesthetizing them with ketamine and xylazine. A 50 l Hamilton sy-
ringe with a 27 gauge needle was mounted on a micromanipulator to
inject the hyaluronidase into the lateral ventricle. We used the following
coordinates from bregma: 1 mm anterior, 4 mm lateral, and 3 mm deep.
The dose of hyaluronidase was calculated based on its previous use in rats
to treat spinal cord and cerebral injury and in our initial experiments,
showing major reduction in HA after hyaluronidase treatment. The se-
verity of IVH, measured by ultrasound, was similar between the compar-
ison groups. In another set of experiments, HA oligosaccharide (10
monosaccharide unit; Hyalose) in a dose of 10 g or vehicle (saline) was
injected into each of the two lateral ventricles, in the same fashion as the
hyaluronidase.
Human subjects. The Research Administration of New York Medical
College (Valhalla, NY) approved the use of autopsy brain samples
from premature infants for this study. The postmortem materials
included forebrain tissue harvested from premature infants [23–27
gestational weeks (gw)] with and without IVH of 5 d of postnatal
age and 18 h postmortem (Table 1). We excluded premature infants
with hypoxic-ischemic encephalopathy, meningitis, culture proven
sepsis, major brain malformation, and chromosomal defects. In this
study, we described intermediate zone embryonic white matter syn-
onymously with white matter, and cerebral cortex for the cortical
plate (Bystron et al., 2008).
Immunohistochemistry. Approximately 3-mm-thick coronal slices at
the head of caudate nucleus from human brains and 2-mm-thick slices
taken at the level of the midseptal nucleus from rabbit forebrains were
processed and immunolabeled as described previously (Dummula et al.,
2011). The primary antibodies used in experiments included rabbit hya-
luronan synthase (HAS) 1 (HAS1; AIVA System Biology), mouse HAS2
(Santa Cruz Biotechnology), rabbit HAS3 (AIVA System Biology),
mouse l caspase 3 (Thermo Fisher Scientific), goat Ki67 (Cell Marque),
Correspondence should be addressed to Dr. Praveen Ballabh, Regional Neonatal Center, Maria Fareri Children’s
Hospital at Westchester Medical Center, Valhalla, NY 10595. E-mail: pballabh@msn.com.
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goat Olig2 (R & D Systems), mouse GFAP (Sigma), rat myelin basic
protein (MBP; Abcam), mouse adenomatous polyposis coli (EMD
Chemicals), goat PDGFR (R & D Systems), mouse myelin-associated
glycoprotein (MAG; Abcam), mouse CD44 (Novus Biologicals), mouse
TLR2 (Abcam), mouse TLR4 (Abcam), biotinylated O4 monoclonal an-
tibody (from Dr. Rashmi Bansal, Farmington University of Connecti-
cut), goat Iba1 (Abcam), and mouse CD11B (AbD Serotec), goat TSG-6
antibody (R & D Systems), and rabbit inter--inhibitor (Dako).
Western blot analyses. Western blot analyses were performed as de-
scribed previously (Ballabh et al., 2007). Briefly, homogenates made
from brain slice taken at the level of the midseptal nucleus were quanti-
fied for protein using a BCA protein assay kit (Thermo Fisher Scientific).
Equal amounts of protein (10 –20 g) were loaded onto 4 –15% or
4 –20% gradient precast gels (Bio-Rad), depending on the molecular
weight of the target protein. Separated proteins were transferred onto
polyvinylidene difluoride membranes by electrotransfer. Membranes
were incubated overnight with primary antibodies and target proteins
were detected with an ECL system by using secondary antibodies conju-
gated with horseradish peroxidase (Jackson Immunoresearch). The blots
from each experiment were run two to three times and were densito-
metrically analyzed using ImageJ. Optical density values were normal-
ized to  actin.
Estimation of hyaluronan by fluorophore-assisted carbohydrate electro-
phoresis. HA contents in rabbit brain slice were measured as described
previously (Lauer et al., 2009). Briefly, forebrain slices taken at the level of
the midseptal nucleus were digested with proteinase K, and HA was
recovered by ethanol precipitation. The HA was digested to disaccharides
at 37°C overnight using hyaluronidase SD (Seikagaku America) and then
labeled with 2-aminoacridone (Life Technologies). The labeled HA di-
saccharides were separated by gel electrophoresis using a Bio-Rad mini-
PROTEAN Tetra system. After electrophoresis, the gels were imaged in
their plates on a UV transilluminator (myEC imager; Thermo Fisher
Scientific) at 365 nm using a CCD camera. The HA disaccharide bands
were quantified using ImageJ.
Quantification of HA by ELISA-like assay and analysis of hyaluronan
molecular weight distribution by agarose gel electrophoresis. HA, extracted
Figure 1. IVH does not affect total HA levels in preterm rabbits and humans. A, Cryosections from the forebrain of rabbit pups were labeled with HABP. Note comparable HA between sections from
pups with and without IVH in periventricular white matter and lack of HA reactivity in hyaluronidase-treated pups. Few GFAP  astrocytes coexpressed HA (arrowheads). However, O4  OPC did not
colocalize with HA signals. B, Representative fluorophore-assisted carbohydrate electrophoresis on rabbit forebrain homogenates showing similar levels of HA in pups with and without IVH at days
3, 7, and 14. However, levels of HA were low in hyaluronidase-treated animals. Data are mean  SEM (n  6 –11 each group). HA levels were significantly reduced in hyaluronidase-treated pups.
***p  0.001 (no IVH controls vs hyalase-treated pups with IVH); ###p  0.001 (IVH pups vs hyalase-treated pups with IVH). C, HA levels were measured by ELISA and were found comparable
between pups with and without IVH at both days 3 and 7. However, HA levels were markedly reduced in hyaluronidase-treated pups. ***p  0.01 (no IVH vs hyalase); ###p  0.01 (no IVH vs
hyalase); mean  SEM. D, Representative immunofluorescence of cryosections from 23 gw infants labeled with HABP show similar reactivity to HABP in infants with and without IVH. Immunore-
activities of few GFAP  astrocytes overlapped with HA (arrowhead). However, O4  OPCs and MAP2  neurons did not colocalize with HA signals. E, Representative fluorophore-assisted
carbohydrate electrophoresis on forebrain homogenates from preterm infants. Data are mean  SEM (n  4 each group). HA levels were similar in infants with and without IVH. F, Coronal brain
slice through frontal lobe of E29 rabbit kit show normal slit-like ventricle (arrows, top), moderate hemorrhage in the ventricle (arrowheads, middle), and severe hemorrhage resulting in fusion of
the two ventricles (arrows, bottom). Scale bars: A, D, 20 m; F, 1 cm.
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from rabbit brains by proteinase K digestion, was quantified by ELISA-
like assay, as described previously (Haserodt et al., 2011). Agarose gel
electrophoresis was performed on 2 mm coronal slices taken from the
forebrain at the level of the midseptal nucleus, based on a previous de-
scription (Lauer et al., 2009).
Size exclusion chromatography. Briefly, HA was extracted from rabbit
brains by proteinase K digestion and purified by ethanol precipita-
tion. Nucleic acids were subsequently digested with Benzonase (EMD
Millipore) and purified by ethanol precipitation. Chromatography
columns were packed with Sephacryl S-1000 and equilibrated in 0.5 M
ammonium acetate. Calibration was accomplished by running 2500,
1000, 500, 250, 100, and 10 kDa Select-HA standards (Hyalose) on the
columns. The mobile phase was pumped at 0.5 ml/min, collecting 1
ml fractions in borosilicate tubes in an automated fraction collector.
An aliquot of each fraction was lyophilized to dryness, resuspended in
0.1 M ammonium acetate, pH 7.0, and digested with Streptomyces
hyaluronidase overnight at 37°C. The samples were then lyophilized
to dryness, labeled with 2-aminoacridone, and incubated overnight at
37°C. The samples were analyzed by electrophoresis and the bands
quantified using Image J software, as described previously (Lauer et
al., 2013a).
Stereological assessment of myelin and astrocytes in the WM and electron
microscopy. These evaluations were performed as in our prior publication
(Dummula et al., 2011).
RT-qPCR. Gene expression was performed by real time PCR on coro-
nal slices taken from forebrain at the level of the midseptal nucleus, as
described previously (Ballabh et al., 2007). The nucleotide sequence of
primers used for RT-qPCR using SYBR green and TaqMan chemistry are
described in Table 2.
Statistics and analysis. Data are expressed as means  SEM. For studies in
rabbits, the expression of MBP, MAG, CNPase, and GFAP and cell counts
were compared between three groups [no IVH, vehicle-treated, and hya-
luronidase- or HA oligosaccharide of 10 monosaccharide length (HA10)-
treated pups] using one-way ANOVA. HA, gene expressions of bHLH
transcription factors, TNF, CD44, TLR2/4, interferon, TSG-6, and pro-
tein levels of MBP were compared between three groups at days 3 and 7 using
two-way ANOVA with repeated measures. In addition, differences in
HAS1–HAS3 expression between pups with and without IVH were com-
pared at days 3 and 7 by two-way ANOVA with repeated measures. For
studies on human tissues, we compared HAS1–HAS3, HA, CD34, TLR2/4,
HC–HA, and TSG activity between infants with and without IVH in three
brain regions (cortex, white matter, and germinal matrix), using two-way
ANOVA with repeated measures. The repeated factor was applied to the
brain regions. All post hoc comparisons were done by Bonferroni’s compar-
ison test at the 0.05 significance level.
Results
IVH does not affect total HA levels in preterm rabbit pups
and human infants
To compare HA levels between premature rabbit pups with and
without IVH, we labeled coronal sections from the forebrain with
hyaluronan-binding protein (HABP). We found that HA was
expressed throughout the gray matter, WM, and periventricular
ganglionic eminence (GE) and that the HA expression (HABP
staining) was comparable in these regions between pups with and
without IVH at postnatal days 3, 7, and 14 (Fig. 1A). Double
labeling of HABP with O4 and GFAP antibodies revealed that HA
was predominantly expressed in the extracellular matrix, and its
expression was weak to absent on O4 OPCs (Fig. 1A). There
were focal areas of colocalization between GFAP and HA, consis-
tent with the fact that astrocytes produce HA. We next quantified
HA by fluorophore-assisted carbohydrate electrophoresis on
rabbit forebrain homogenates, which confirmed that HA levels
were similar between pups with IVH and without IVH (glycerol
treated) at days 3, 7, and 14 (Fig. 1B). Importantly, intracerebro-
ventricular (ICV) hyaluronidase treatment almost totally elimi-
nated HABP binding in immunolabeled sections (Fig. 1A) and
reduced HA levels by more than 10-fold in forebrain homoge-
nates (Fig. 1B). Comparable HA levels between rabbits with and
without IVH and its marked reduction by hyaluronidase treat-
ment were further validated by ELISA (Fig. 1C).
We next evaluated HA expression in the forebrain of pre-
mature infants (23–27 gw) with and without IVH (Table 1).
Consistent with premature rabbits, HA expression in the GE
and the adjacent WM was comparable between human infants
with and without IVH (Fig. 1D). HA expression was almost
absent on MAP2  neurons. However, HA was expressed by
O4  OPCs and a few GFAP  astrocytes. Quantification of HA
in homogenates from the GE and periventricular WM showed
a trend toward decrease only in the GEs of infants with IVH
compared to controls without IVH (Fig. 1E). However, the
difference was not statistically significant.
To determine HA size, we purified the HA isolated from the
rabbit brains and analyzed the extract by agarose gel electropho-
resis. The resulting blue staining in agarose gel electrophoresis
consisted of HA of molecular weight ranging from 50 –2500 kDa




(kg) IVH/no IVH Cause of death
26a Male 0.810 IVH grade 3 Clinical sepsis
23a Male 0.57 IVH grade 2 Clinical sepsis
23a Female 0.58 IVH grade 3 Respiratory failure
24a Male 0.64 IVH grade 4 Pulmonary hemorrhage
24 Male 0.6 IVH grade 4 Clinical sepsis
23 Female 0.52 IVH grade 3 Respiratory failure
23 Female 0.53 no IVH Respiratory failure
25 Female 0.71 no IVH Metabolic acidosis,
respiratory failure
23a Male 0.45 no IVH RDS, respiratory failure
24a Male 0.61 no IVH Clinical sepsis
25a Male 0.73 no IVH Metabolic acidosis,
respiratory failure
24a Female 0.56 no IVH Respiratory failure
aIndicates autopsy samples used for experiments shown in Figure 6. RDS, Respiratory distress syndrome.
Table 2. Nucleotide sequence of primers
Accession # Sense Antisense
HAS1 NM_001523.2 TGTGTATCCTGCATCAGCGGT CTGGAGGTGTACTTGGTAGCA
TAACC
HAS2 NM_001082010 TTCAGTGAAGTCATGGGCAGGGAA GTTCGACAAGACCAGTTGGGT
TAC
HAS3 NM_001082709.1 GGTACCATCAGAAGTTCCTAGGCAGC GAGGAGAATGTTCCAGATGCG
TLR2 NM_001082781.1 AGGTGCCTCCTTGTTACCTATGCT AGATGAAGTTGTTCCCTCCGGC
TT
TSG-6 NM_001082311.1 ACTCAAGTATGGTCAGCGTATTC TCTCCACAGTACCTTCCTACAA
GFAP NG_008401 ACTCAATGCTGGCTTCAAGGAGAC ATGTAGCTGGCAAAGCGGTCA
TTG
Id2 XM_002723742.1 CCATGAGCCTGCTCTACAA GTGCTGCAGGATTTCCATTT
Id4 NM_001546 GGCATAATGGCAAATCCTTCAAG TCACAAGAGATGGGACAGTAGC
Olig1 XM_002716810.1 AGGTCATCCTGCCCTACTC CCAGCAGCAGGATGTAGTT
Olig2 XM_002716698.1 TTCAAGTCCTCCTCGTCCA GGCTCGGTCATCTGTTTCTT
Sox10 XM_002723532 AAGCCTTTCTGTCTGGCTCACT TCAGGTCCTGGATAGAGGGT
CATT
GAPDH NM_001082253.1 GCGTGAACCACGAGAAGTAT CCTCCACAATGCCGAAGT
The gene expression for hyaluronidase 1 (assay ID, Hs00201046_m1) and hyaluronidase 2 (Hs00201046_m1)
in human samples and TNF (Oc3397716_g1), IL1 (Oc03823250_s1), TLR2 (Oc03824728_s1), TLR4
(Oc03398502_m1), CD44 (Hs01075861_m1), and GAPDH (Oc03823402_g1) were assayed using primers plus MGB
TaqMan probes from Invitrogen.
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(Fig. 2A). Optical density measurements revealed that 500 –1000
kDa fragments showed a trend toward reduction in pups with
IVH compared to glycerol-treated controls without IVH at day 3
(Fig. 2B). However, the comparison for HA fragments was not
statistically significant between pups with and without IVH at
days 3, 7, and 14. To validate the findings of agarose gel electro-
phoresis, we performed size exclusion chromatography at days 3
and 7, which also showed comparable levels of HA fragments
between pups with and without IVH at both days 3 and 7 (Fig.
2E,F). In human infants, the distribution of HA molecular
weight fragments, assessed by agarose gel electrophoresis, were
comparable between neonates with and without IVH (Fig. 2C,D).
Together, the data reveal that the onset of IVH does not affect
total HA levels in rabbits or humans compared to controls with-
out IVH.
HAS2 is elevated in both humans and rabbits with IVH, but
not HAS1 and HAS3
To study the dynamics of HA synthesis and degradation, we eval-
uated expression of HAS1, HAS2, and HAS3 as well as hyaluron-
idase enzymes in both preterm humans (23–27 gw) and rabbits
(E29) with and without IVH. Immunolabeling of forebrain sec-
tions showed that HAS2 expression was more abundant in
periventricular GEs of infants with IVH compared to controls
without IVH (Fig. 3A). However, HAS1 and HAS3 expression
was comparable between preterm infants with and without IVH.
Double labeling revealed that all three synthases were expressed
abundantly on GFAP astrocytes, and weakly on doublecortin-
positive (DCX) neurons and Olig2 OPCs (HAS3 data not
shown). Western blot analyses confirmed that HAS2 levels were
higher in the GEs of preterm infants with IVH compared to con-
trols without IVH (p  0.003; Fig. 3B), but not in the cortex or
WM. HAS1 and HAS3 expressions were comparable between
infants with and without IVH.
In rabbits, both mRNA and protein expression of HAS1 and
HAS3 in the forebrain were comparable between pups with and
without IVH at days 3 and 7 (Fig. 4A–E; data on rabbit HAS3
protein levels not shown). While HAS2 mRNA accumulation was
lower in pups with IVH compared to controls at day 3 (p  0.03,
not at day 7), protein levels were higher in the forebrain of pups
with IVH relative to pups without IVH at both days 3 and 7 (p 
0.003 and 0.001, respectively; Fig. 4C,D). This difference might be
attributed to alteration in the post-translational modifications of
HAS2 enzymes.
Figure 2. HA size analysis by agarose gel electrophoresis and size exclusion chromatography. A, B, Agarose gel electrophoresis shows HA fragments (50 –2500 kDa) in rabbit pup brain
homogenates. HMW HA fragments (500 –1000 kDa) are comparable between pups with and without IVH compared to controls without IVH at days 3, 7, and 14. Boxed area shows HMW HA
fragments of 500 –1000 kDa at day 3. C, D, Agarose gel electrophoresis was performed on brain homogenates from premature infant after digestion with hyaluronidase. HMW HA fragments
(500 –1000 kDa) are similar between infants with and without IVH in both white matter and GE. The bar charts shows mean  SEM (n  5 each group). E, F, Data are mean  SEM (n  3 pups
each group). HA size was evaluated by size exclusion chromatography on samples from each of three groups of pups as indicated. Calibration was accomplished by running 2500, 1000, 500, 250, 100,
and 10 kDa Select-HA standards. Comparisons between pups with and without IVH were insignificant at both days 3 and 7.
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RT-qPCR data revealed that hyaluronidase-1 (Hyal-1) and
Hyal-2 mRNA expressions were similar between human infants
with and without IVH (Fig. 4F,G). PH20 mRNA expression
could not be detected in human brains with commercially avail-
able two TaqMan primers (Invitrogen). Together, HAS2 en-
zymes are elevated in both rabbits and humans with IVH.
CD44, TLR2, and TLR4 are elevated in the GEs of infants
with IVH
Since HA fragments signal responses through CD44 and the
TLR2/4 receptors (Jiang et al., 2011), we assayed their expression
in the forebrain of premature infants with and without IVH.
Immunolabeling of forebrain sections demonstrated that CD44
expression was more abundant in the GEs of premature infants
with IVH compared to controls without IVH (Fig. 5A). In addi-
tion, CD44 immunoreactivity was significantly higher in the GE
compared with the embryonic WM and neocortex of infants both
with and without IVH. Double immunolabeling revealed that
CD44 was expressed on GFAP astrocytes, O4 OPCs, and
Iba1 microglia, but not on DCX neurons. Western blot anal-
yses confirmed that CD44 levels were elevated in the GEs of in-
fants with IVH relative to controls without IVH (p  0.001), but
not in the neocortex or WM (Fig. 5B).
We next assessed TLR2 expression in premature infants with
IVH compared to controls without IVH. We noted higher immu-
noreactivity of TLR2 in the GEs of premature infants with IVH
than in controls without IVH (Fig. 5A). TLR2 was expressed on
several Iba1 microglia and a few GFAP astrocytes, but not on
Olig2 OPCs or DCX neurons. Consistent with immunohisto-
chemistry, Western blot analyses showed higher levels of TLR2 in
the GEs of premature infants with IVH compared to controls
without IVH (p  0.011; Fig. 5B).
Similar to TLR2 expression, TLR4 immunoreactivity was
more abundant in the periventricular GEs of infants with IVH
compared to controls without IVH. TLR4 was expressed on
GFAP astrocytes, DCX neurons, and several O4 OPCs, but
not on Iba1 microglia (Fig. 5A). TLR4 protein quantification by
Western blot analyses revealed that TLR4 expression was elevated
in the GEs of human infants with IVH compared to controls (p 
0.02; Fig. 5B), but not in the WM or cortex. Together, IVH results
in higher expression of HA receptors—CD44, and TLR2/4 —in
the periventricular GE. Since all OPCs originate from GE prena-
Figure 3. HAS2 enzyme is upregulated in humans with IVH. A, Representative immunofluorescence of cryosections from 23 gw infant labeled with HAS1 (top) and HAS2 (bottom). Insets show
high-magnification images. HAS2 immunoreactivity was strong in ganglionic eminence of infants with IVH and weak in infants without IVH. However, HAS1 was similarly expressed in infants with
and without IVH. Note HAS1 and HAS2 are expressed on GFAP  astrocytes (arrowheads) and a few O4  OPCs. HAS1 immunoreactivities were weak to absent on DCX  neurons, but HAS2 was
expressed on DCX  neurons (arrowheads). Scale bars: 20 m. B, Western blot analyses were performed for HAS1, HAS2, and HAS3 on homogenates made from tissues taken from cortical plate
(cortex), embryonic WM, and GEs of preterm infants with and without IVH, as indicated. The bar charts show mean  SEM (n  6 each). Values were normalized to  actin levels. HAS2 levels were
elevated in the ganglionic eminence of infants with IVH compared to controls without IVH, but not HAS1 or HAS3. **p  0.01 (no IVH vs IVH in the ganglionic eminence).
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tally to populate the white matter (Kessaris et al., 2006), elevated
expressions of CD44 and TLR2/4 in the GE is likely to impact
production and maturation of OPCs as well as myelination of the
adjacent white matter.
Hyaluronidase treatment restores myelination
Because HA inhibits maturation of OPCs and myelination in cell
culture experiments and models of demyelination (Back et al.,
2005; Sloane et al., 2010), we compared myelination among three
groups of pups at day 14: (1) pups without IVH (glycerol treated),
(2) vehicle-treated pups with IVH (glycerol treated), and (3)
hyaluronidase-treated pups with IVH (glycerol treated). To clar-
ify, intraperitoneal glycerol was used to induce IVH, and ICV
vehicle (saline) was administered for comparison with ICV hyal-
uronidase. The severity of IVH was comparable between vehicle-
and hyaluronidase-treated groups (ventricular volume, 192  37
mm 3 vs 189  36 mm 3 for vehicle and hyalase, respectively), as
measured by head ultrasound. Stereological analyses of MBP in
immunolabeled sections demonstrated that the volume fractions
(myelin load) of MBP in the corpus callosum and corona radiata
were significantly reduced in pups with IVH relative to controls
without IVH (p  0.004) and that ICV hyaluronidase injection
restored the expression of MBP (p  0.049; Fig. 6A). Accord-
ingly, Western blot analyses verified that MBP and MAG levels
were diminished in pups with IVH compared to controls without
IVH (p  0.001 both) and that hyaluronidase treatment signifi-
cantly increased MBP and MAG expression in pups with IVH
(both p  0.001; Fig. 6B,C).
Ultrastructural evaluation of the corpus callosum and corona
radiata revealed that myelinated axons were fewer in pups with
IVH compared to controls without IVH (p  0.05; Fig. 6D) and
that hyaluronidase treatment significantly amplified the number
of myelinated axons in pups with IVH (p  0.05). Moreover, the
g ratio was comparable in the three groups of pups (0.769  0.01
vs 0.76  0.002 vs 0.758  0.012, in pups without IVH with IVH
and hyaluronidase treatment, respectively). This suggests that
hyaluronidase treatment enhances myelination and restores mor-
phology of the myelin sheath.
Since myelination is abundant at day 14 in our animal model,
we selected two epochs— day 7 and day 14 —to assess progress in
myelination in the three sets of rabbit pups. We found that MBP
and MAG expressions were 10-fold less at day 7 relative to day
Figure 4. HAS2 expression higher in rabbits with IVH. A, B, HAS1 mRNA expression was comparable between rabbit kits with and without IVH at both days 3 and 7. Western blot analyses for HAS1
was performed on lysates made from forebrain slices of rabbit kits with and without IVH, as indicated. HAS1 protein levels were comparable between kits with and without IVH. C, D, HAS2 mRNA
expression was less in rabbit kits with IVH compared to controls at day 3, but not at day 7. Western blot analyses for HAS2 were performed on lysates made from forebrain slices of rabbit kits with
and without IVH, as indicated. Note that HAS2 levels are elevated in kits with IVH relative to controls without IVH at both days 3 and 7. *p  0.05; **p  0.01; ***p  0.001 (for IVH vs no IVH). E,
HAS3 mRNA was similar between kits with and without IVH. F, G, Human Hyal-1 and Hyal-2 mRNA expressions were similar between infants with and without IVH at both days 3 and 7. The bar charts
shows mean  SEM (n  5 each group).
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14 in control pups without IVH and hyaluronidase-treated
pups. More importantly, MBP expression was comparable be-
tween three groups—pups without IVH and vehicle- and
hyaluronidase-treated pups with IVH—at day 7 on both immu-
nohistochemistry with stereological quantification and Western
blot analyses (Fig. 6E). This suggested that the process of myeli-
nation was predominant during days 7–14, and arrested myeli-
nation in pups with IVH was restored by hyaluronidase
treatment during this period.
Hyaluronidase treatment does not affect astrogliosis
HA accumulates in the CNS lesions, limits gliosis, and regulates
glia scar formation (Struve et al., 2005; Cargill et al., 2012). There-
fore, we hypothesized that hyaluronidase treatment might reduce
astrogliosis in rabbit pups with IVH. However, GFAP expression
was comparable between vehicle- and hyaluronidase-treated
pups with IVH in the corpus callosum and corona radiata on
both stereological quantification of immuolabeled sections and
Western blot analyses (Fig. 7A,B).
Since hyaluronidase treatment enhanced myelination in pups
with IVH, we reasoned that this might affect myelination or gli-
osis in healthy pups. To this end, we compared MBP and GFAP
levels in the vehicle- and hyaluronidase-treated healthy pups at
day 14 (data not shown). We found that hyaluronidase treatment
did not significantly affect myelination or astrogliosis in healthy
pups without IVH.
ICV hyaluronidase promotes maturation of OPC and
enhances transcription of Olig1, Olig2, and MBP genes
Since HA inhibits OPC maturation (Back et al., 2005; Sloane et
al., 2010), we postulated that hyaluronidase treatment might
affect proliferation and maturation of OPCs. To assess prolif-
eration of OPCs in the corona radiata and corpus callosum,
we compared (1) pups without IVH (glycerol treated), (2)
vehicle-treated pups with IVH, and (3) hyaluronidase-treated
pups with IVH for cycling (Ki67 ) and total OPCs—
PDGFR  and Olig2 —at day 3. Severity of IVH was similar
between vehicle- and hyaluronidase-treated groups (ventric-
ular volume, 197  38 mm 3 vs 190  31 mm 3 for vehicle- and
hyalase-treated pups, respectively). The densities of total
PDGFR  cells were similar between the three sets of pups
(Fig. 8A). However, the cycling PDGFR  cells were reduced
Figure 5. CD44, TLR2, and TLR4 are elevated in humans with IVH. A, Typical immunolabeling of cryosections from 23 gw infants with CD44- (top), TLR2- (middle), and TLR4-specific (bottom)
antibodies. Insets show high-magnification images. Note that all the three receptors show stronger and more widespread immunoreactivity in infants with IVH relative to controls without IVH. Note
that CD44 and TLR2 were expressed on GFAP  astrocytes (arrowheads) and Iba1  microglia (arrows), but not on OPC or DCX  neurons. TLR4 were expressed on DCX  neurons, astrocytes
(arrowheads), and a few OPC (block arrows). Scale bars: 20 m. B, Representative Western blot analyses performed on tissues from cortical plate, embryonic WM, and GEs of preterm infants with
and without IVH using CD44- (85–95 kDa) and TLR2- and TLR4-specific (90 kDa) antibodies, as indicated. The bar charts show mean  SEM (n  6 each). Values were normalized to  actin levels.
All three receptors were elevated in GEs of infants with IVH compared to controls without IVH. Both CD44 and TLR2 were elevated in the GE relative to the neocortex and white matter among infants
with IVH, but not infants without IVH. *p  0.05, ***p  0.001 (no IVH vs IVH in the GE); †p  0.01 (GM vs WM in pups with IVH); ‡p  0.01 (GE vs cortex in pups with IVH).
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in pups with IVH ( p  0.047) compared to controls without
IVH, and hyaluronidase treatment did not affect their density.
Both total and cycling Olig2 cells showed a trend toward de-
cline in pups with IVH compared to controls without IVH at
day 3, and hyaluronidase treatment did not significantly affect
their density (Fig. 8B).
We next evaluated the effect of hyaluronidase treatment on
OPC maturation. We found that the population of O4APC
cells was significantly reduced in pups with IVH relative to con-
trols without IVH (p  0.001), and hyaluronidase treatment
significantly increased the density of O4APC OPCs (p 
0.001) in the corona radiata and corpus callosum (Fig. 8C). This
suggests that hyaluronidase treatment restores the maturation of
OPCs in pups with IVH. We also found that the levels of CNPase
(2,3-cyclic nucleotide-3-phosphodiesterase), measured by
Western blot analyses, were significantly reduced in pups with
IVH compared to controls (p  0.001) at day 14 and that hyal-
uronidase treatment restored the expression of CNPase (p 
0.001; Fig. 8D). Together, hyaluronidase treatment favors matu-
ration of OPCs.
As OPC matures from the stage of specification to the termi-
nal differentiation, Olig1, Olig2, and Sox10 transcription factors
enhance maturation, whereas Id2 and Id4 have inhibitory influ-
ences (Nicolay et al., 2007). qRT-PCR revealed that mRNA ex-
pressions of Olig2 and MBP were significantly reduced in pups
with IVH at day 7 (p  0.008 and 0.05, respectively), and that
hyaluronidase treatment significantly elevated levels of Olig1,
Olig2, and MBP mRNA compared to vehicle controls at day 7
(p  0.05, 0.036, and 0.048, respectively; data not shown). Addi-
tionally, ID4 expression was elevated in pups with IVH (p 
0.036), and hyaluronidase treatment reduced its level (p 
0.001). Together, the data show that hyaluronidase treatment
Figure 6. Hyaluronidase treatment restores myelination in rabbits with IVH. A, Representative immunofluorescence of MBP in the corona radiata of day 14 pups. Volume fractions of MBP were
higher in the corpus callosum and corona radiata of hyaluronidase-treated pups compared with vehicle-treated controls with IVH. V, Ventricular side. B, Typical Western blot analysis for MBP in the
forebrain of premature rabbit pups, as indicated, at day 14. Adult rat brain was used as a positive control. Each lane represents a lysate from a whole coronal slice taken at the level of midseptal nucleus
of one brain. MBP expression was higher in hyaluronidase-treated pups compared with vehicle-treated pups. C, Western blot analysis for MAG in the forebrain of pups as indicated at day 14. Adult rat
brain was used as a positive control. MAG expression was higher in hyaluronidase-treated pups compared with vehicle-treated controls. D, Typical electron micrograph from rabbit pups without and
with IVH, and pups with IVH treated with hyaluronidase at day 14. Note that myelinated axons were fewer in pups with IVH compared to controls without IVH and that hyaluronidase treatment
significantly increased the number of myelinated axons in pups with IVH. E, Representative Western blot analyses for MBP and MAG for three groups of pups (as indicated) at days 7 and 14. Note the
similar expression of MBP and MAG in the three sets of pups at day 7. MBP levels at day 14 were 10-fold higher compared to day 7 in pups without IVH and hyaluronidase-treated pups with IVH.
*p  0.05 (pups with vs without IVH), **p  0.01 (no IVH pups day 7 vs day 14), ***p  0.001 (pups with vs without IVH); #p  0.05 (vehicle- vs hyaluronidase-treated pups with IVH), ##p 
0.001 (pups with IVH day 7 vs day 14), ###p  0.001 (vehicle- vs hyaluronidase-treated pups with IVH); ‡‡p  0.001 (pups with IVH day 7 vs day 14). Scale bars: A, 200 m; D, 1 m. Data are
mean  SEM (n  5 each group).
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restores expression of MBP, Olg1, Olig2, and ID4 bHLH tran-
scription factors in pups with IVH.
Hyaluronidase treatment suppresses proinflammatory
cytokines, microglial infiltration, and HA receptors
HA and its binding receptors regulate transcription of inflamma-
tory genes, recruitment of inflammatory cells, and release of
cytokines (Petrey and de la Motte, 2014). Therefore, we assessed
the effect of hyaluronidase treatment on IVH-induced inflamma-
tion. We found that the number of Iba1 and CD11b (acti-
vated) microglia were higher in pups with IVH compared to
controls (glycerol treated) without IVH (p  0.01 and 0.001,
respectively), and that hyaluronidase treatment reduced their
density (p  0.04 and 0.001, respectively; Fig. 9A,B).
We next quantified mRNA expression of proinflammatory
cytokines, including TNF, IL-1, and  interferon, by qRT-
PCR (TaqMan probes). We noted that both TNF and IL-1
expression were elevated in pups with IVH compared to con-
trols at day 3 ( p  0.017 and 0.02, respectively), but not at day
7. Importantly, hyaluronidase treatment reduced their expres-
sion ( p  0.009 and 0.015, respectively; Fig. 9C). -interferon
levels were comparable between rabbits with and without
IVH.
We then assayed mRNA expression of CD44 and TLR2/4
receptors by qRT-PCR (TaqMan probes). We found that
CD44 gene expression was elevated in pups with IVH com-
pared with controls at both days 3 and 7 (both p  0.001; Fig.
9D), and hyaluronidase treatment reduced CD44 levels at both
days ( p  0.006 and 0.03, respectively). TLR2 and TLR4
mRNA expressions were also elevated in pups with IVH rela-
tive to controls at day 3 ( p  0.001 and 0.002, respectively; Fig.
9D), but not at day 7. Importantly, hyaluronidase treatment
significantly reduced TLR4 expression ( p  0.005), but not
TLR2 expression.
Consistent with qRT-PCR, immunolabeling showed that
CD44 and TLR4 were more abundantly expressed in the periven-
tricular WM of pups with IVH compared to controls without
IVH, and that hyaluronidase treatment significantly reduced
their immunoreactivity (data not shown). Western blot analyses
confirmed that TLR4 levels were elevated in pups with IVH com-
pared with controls at day 3 (p  0.05), and that hyaluronidase
treatment reduced the TLR4 expression (p  0.04; Fig. 9E). To-
Figure 7. Hyaluronidase treatment does not alter GFAP expression. A, Representative immunofluorescence of cryosections from pups (day 14) labeled with GFAP antibody is shown, as indicated.
Note abundant hypertrophic astrocytes in vehicle- and hyaluronidase-treated pups with IVH. Scale bars: 50 m. V, Ventricular side. Hyaluronidase treatment did not affect volume fraction of
astroglial fibers compared to vehicle controls on stereological analyses. B, Western blot analyses for GFAP were performed in forebrain homogenates of pups (day 14). Adult rat brain was the positive
control. Values were normalized to  actin. Hyaluronidase treatment did not affect GFAP expression in pups with IVH. The graphs show mean  SEM (n  5 each). C, GFAP mRNA expression was
not affected by hyaluronidase treatment. *p  0.05; **p  0.01; ***p  0.001 (no IVH vs IVH).
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gether, the data show that hyaluronidase treatment reduced pro-
inflammatory cytokines, microglial infiltration, CD44, and TLR4
expression.
Hyaluronidase administration restores neurological recovery
We next performed neurobehavioral evaluations of three sets
of preterm pups at day 14 (Table 3), as described previously
(Chua et al., 2009). Vehicle- and hyaluronidase-treated
groups were balanced with respect to the severity of IVH (ven-
tricular volume, 195  27 mm 3 vs 187  26 mm 3 for vehicle
and hyalase, respectively). We found significant weakness in
the hind legs of three vehicle-treated pups, with IVH manifest-
ing as clumsiness in the gait, whereas none of the pups in
hyaluronidase-treated or healthy control group (no IVH)
showed any evidence of weakness in the legs. The scores for
gait were significantly higher in hyaluronidase-treated pups
than in vehicle controls ( p  0.05). The average distance
walked in 60 s was farther in hyaluronidase-treated pups com-
pared with vehicle controls ( p  0.04). The percentage of
pups showing an inability to hold their position on a ramp
pitched at 60° inclination for 15 s or longer was more in
hyaluronidase-treated pups compared to saline controls (0 vs
33%). Scores for the righting reflex were significantly better in
hyaluronidase-treated pups compared to vehicle-treated
controls ( p  0.05). There was no difference in sensory and
cranial nerve assessment of the three sets of rabbit pups. Im-
portantly, we did not observe any apparent adverse effect at-
tributable to hyaluronidase treatment among pups with IVH
receiving this medication.
IVH induces TSG-6 activity and synthesis of HC–HA
complexes
TSG-6 expression is upregulated in response to proinflammatory
mediators, and this catalyzes the covalent transfer of HCs from
II to HA to produce a pathological form of HA (HC–HA com-
plex; Milner and Day, 2003; Colón et al., 2009). Since IVH in-
duces an inflammatory response (Georgiadis et al., 2008), we
evaluated autopsy samples from preterm infants with and with-
Figure 8. Hyaluronidase administration promotes OPC maturation. A, Representative immunofluorescence is shown of cryosections from 3-d-old pups double labeled with PDGFR- and
Ki67-specific antibodies. Note that all PDGFR  cells are comparable in the three groups as indicated; cycling PDGFR  cells are reduced in pups with IVH, and hyaluronidase treatment does not
affect these cells. B, Representative immunofluorescence is shown of cryosections from 3-d-old pups double labeled with Olig2- and Ki67-specific antibodies. Note that total and cycling Olig2  cells
show a trend toward reduction in pups with IVH (compared to no IVH controls) and an increase in hyaluronidase-treated pups (relative to IVH pups). C, Cryosections were double labeled with O4
(arrowhead) and APC antibodies. Note the reduced number of cells colabeled with O4 APC  (arrowhead) in pups with IVH compared to vehicle controls and hyaluronidase treatment increases the
number in this subset of cells. Graphs show mean  SEM (n  5 each). D, Typical Western blot analyses for CNPase on the forebrain lysate of rabbit forebrain at day 14 as indicated. Note that CNPase
expression is reduced in rabbits with IVH and restored after hyaluronidase treatment. *p  0.05, ***p  0.001 (pups with vs without IVH); ###p  0.001 (vehicle- vs hyaluronidase-treated pups
with IVH).
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out IVH for HC–HA (85 kDa). Aliquots of forebrain homoge-
nates were treated with hyaluronidase and incubated for 30 min
at 4°C, followed by 30 min incubation at 37°C, to release HC from
HC–HA complexes. Western blot analyses on these homogenates
using II antibody showed that the HC–HA (85 kDa) levels were
higher in the GEs of preterm infants with IVH compared to con-
trols without IVH (p  0.005; Fig. 10A,B). HC–HA levels in the
WM showed a trend toward increase in infants with IVH com-
pared to controls.
We next evaluated endogenous TSG-6 activity in the brain
extracts by adding HA oligosaccharide (14 monosaccharides).
Endogenous TSG-6 activity was indicated by an appearance of a
HC band (85 kDa), which was formed by transfer of HCs from
II onto HA oligosaccharide. Positive controls were made by
addition of exogenous TSG-6 to the brain extract, which led to
formation of a strong 85 kDa band (Fig. 10C), indicating the
suitability of experimental conditions to assess TSG-6 activity.
We found an increased TSG-6 activity (elevated 85 kDa HC) in
the GEs of infants with IVH compared to controls without IVH
(p  0.025; Fig. 10C,D), but not in the WM. Together, the data
demonstrate greater abundance of HC–HA complexes and
TSG-6 activity in the GEs of infants with IVH compared to con-
trols without IVH.
TSG-6 transfers HC from II to HA in a reversible manner.
However, transfer of HC to HA oligosaccharides (8 –21 oligosac-
charide units) is an irreversible event. We have demonstrated the
utility of this observation by irreversibly swapping HCs from
HC–HA onto a HA oligosaccharide in the synovial fluid of pa-
tients with rheumatoid arthritis, thereby restoring the patholog-
ical HC–HA matrices to their normal state (Lauer et al., 2013b).
Accordingly, aliquots of homogenates made from GEs of infants
with IVH were incubated at 37°C with HA10 (10 monosaccharide
units) for 24 or 72 h. Adding exogenous recombinant TSG-6
resulted in a smear above 250 kDa (Fig. 10, lane 4), indicating
transfer of HCs from II to HA, forming the HC–HA complex.
Importantly, application of both HA10 and exogenous recombi-
Figure 9. Hyaluronidase treatment reduced microglia density, cytokines, CD44, and TLR4 in rabbits with IVH. A, B, Representative immunofluorescence of Iba1 and CD11b are shown in the corona
radiata of day 3 pups, as indicated. Sytox staining was used to label nuclei. Insets show high-magnification views of the boxed area in the image. Both Iba1  and CD11B  microglia were higher
in number in pups with IVH compared to controls without IVH, and hyaluronidase treatment reduces their density. Scale bars: 50 m. C, TNF and IL1 mRNA expression were elevated in IVH
compared to controls with IVH at day 3, and hyaluronidase treatment restored the level.  interferon gene expression was similar in the three groups. D, CD44 mRNA expressions were higher in IVH
compared to controls with IVH at both days 3 and 7, and hyaluronidase treatment restored the level. TLR4 gene expression was elevated in pups with IVH at day 3, but not at P7. Hyaluronidase
treatment reduced TLR4 levels. TLR2 levels were not significantly changed in the three sets of pups at days 3 and 7. E, Western blot analyses for TLR4 on the forebrain lysate of rabbit forebrain at day
3 are shown, as indicated. Note that hyaluronidase treatment reduces TLR4 protein expression in pups with IVH. Data are mean  SEM (n  5 each group). *p  0.05, **p  0.01, ***p  0.001
(pups with vs without IVH); #p  0.05, ##p  0.01, ###p  0.001 (vehicle- vs hyaluronidase-treated pups with IVH).
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nant TSG-6 to the brain extract (lane 5) led to an intense 85 kDa
band, which indicated swapping of the HCs from HC–HA com-
plex onto the HA10 oligosaccharide. Collectively, use of HA10
holds promise in removal of HC from pathological HA in pre-
term infants and possibly in rabbits with IVH.
We next assessed TSG-6 mRNA expressions in preterm rabbit
pups with and without IVH at days 3 and 7. We found that TSG-6
gene expression was significantly higher in pups with IVH com-
pared to controls without IVH at P3 (p  0.009; Fig. 10G), but
not at P7. Accordingly, immunolabeling showed that TSG-6 was
more abundantly expressed in GE and WM of rabbits with IVH
compared to controls without IVH (data not shown). Together,
the data suggest that TSG-6 expression is upregulated in subjects
with IVH, which induces generation of HC–HA complexes in the
brain.
ICV HA oligosaccharide administration reduces
inflammation and promotes myelination
Because HC–HA complexes exhibit proinflammatory activity,
we postulated that removal of HCs from the HC–HA com-
plexes might reduce inflammation and restore myelination in
rabbit pups with IVH. Since HA oligosaccharides are irrevers-
ible HC acceptors, unlike high molecular weight HA, we com-
pared (1) pups without IVH (glycerol treated), (2) pups
vehicle treated with IVH, and (3) HA10-treated pups with
IVH for microglial density and proinflammatory cytokines.
Vehicle was administered intracerebroventricularly, just as
HA10. We found that the densities of both Iba1  and CD11b 
microglia in the periventricular WM were higher in the pups
with IVH compared to controls without IVH at day 3 ( p 
0.01 and 0.001, respectively), and HA oligosaccharide treat-
ment reduced their number in pups with IVH ( p  0.015 and
0.001, respectively; Fig. 11 A, B). Accordingly, TNF and IL1
mRNA accumulation were higher in the pups with IVH com-
pared to glycerol controls ( p  0.001 and 0.004, respectively),
and HA oligosaccharide treatment reduced their levels in pups
with IVH at day 3 ( p  0.001 and 0.036, respectively; Fig.
11C). HA oligosaccharide also reduced TLR4 expression in
pups with IVH at day 3 ( p  0.01), but not CD44 and TLR2
expression (Fig. 11D). Hence, HA oligosaccharide administra-
tion appears to alleviate inflammation by reducing microglial
infiltration, proinflammatory cytokines, and TLR4 levels.
We next evaluated the effect of HA oligosaccharide treatment
on myelination and astrogliosis. Stereological quantification of
immunolabeled sections revealed that the volume fractions (my-
elin load) of MBP in the corpus callosum and corona radiata were
significantly higher in HA oligosaccharide-treated pups with IVH
relative to vehicle controls with IVH (p  0.014; Fig. 12A). West-
ern blot analyses demonstrated that all three—MBP, MAG, and
CNPase—levels were higher in HA oligosaccharide-treated pups
with IVH compared to vehicle controls with IVH (all p  0.001;
Fig. 12B–D). Moreover, GFAP expression—measured by stereo-
logical quantification and Western blot analysis—was similar be-
tween HA oligosaccharide and vehicle-treated pups with IVH
(Fig. 12E). Together, the data demonstrate that HA oligosaccha-
ride treatment enhances myelination without significantly inhib-
iting astrogliosis.
HA oligosaccharide treatment promotes neurological
recovery
We performed neurobehavioral evaluations on the three sets
of preterm pups at day 14: (1) pups without IVH (glycerol
treated), (2) vehicle-treated pups with IVH, and (3) HA
oligosaccharide-treated pups with IVH (Table 4). The three
groups were similar with respect to the severity of IVH (179 
27 vs 172  17 mm 3 for HA10 and vehicle, respectively), as
quantified by head ultrasound. We found that one kit in the
vehicle-treated group had weakness in all four extremities and
was not able to walk at all. In addition, three pups in this group
had significant weakness in the hind legs manifesting as clum-
siness and asymmetry in the gait. In the HA oligosaccharide-
treated pups, one pup had significant weakness in the back
legs. Conversely, none of the pups in the glycerol-treated
control (no IVH) group exhibited significant weakness in the
fore or hind legs. The scores for gait and movement of the hind
leg were significantly higher in HA oligosaccharide-treated
pups than in saline controls ( p  0.05). The average dist-
ance walked in 60 s was farther in HA oligosaccharide-
treated pups compared with vehicle controls (114  17 vs
89.1  12.2 inches). There was no difference in sensory and
cranial nerve assessments of the three sets of rabbit pups.
Overall, HA oligosaccharide-treated pups performed superior
on neurobehavioral scoring compared with vehicle controls.
Discussion
In this study, we showed that the development of IVH increases
the expression of HA-associated receptors (CD44, TLR2, and
Table 3. Neurobehavioral evaluation of hyaluronidase- and vehicle-treated pups








Cranial nerve Aversive response to alcohol 3 (3, 3) 3 (3, 3) 3 (3, 3)
Sucking and swallowing 3 (3, 3) 3 (3, 3) 3 (3, 3)
Motor Motor activity
Head 3 (3, 3) 3 (3, 3) 3 (3, 3)
Fore legs 3 (3, 3) 3 (3, 3) 3 (3, 3)
Hind legs 3 (3, 3) 3 (2.5, 3) 3 (3, 3)
Righting reflexa 5 (5, 5) 4 (3, 5)# 5 (5, 5)**
Locomotion on 30° inclinationb 3 (3, 3) 3 (2.75, 3) 3 (3, 3)
Tonec: Forelimb 0 (0, 0) 0 (0, 0) 0 (0, 0)
Tonec: Hindlimb 0 (0, 0) 0 (0, 0) 0 (0, 0)
Inability to hold their position
at 60°
0% 25% 0%
Inclination for 15 s or less
(latency to slip down
the slope, if 15 s)
Inability to walk more than 60
inches in 1 min (%)
0% 33% 0%
Gaitd 4 (4, 4) 3 (2.5, 4)# 4 (4, 4)*
Motor impairmente 0% 25% 0%
Sensory Facial touch 3 (3, 3) 3 (3, 3) 3 (3, 3)
Pain 3 (3, 3) 3 (3, 3) 3 (3, 3)
Values are the median and interquartile range. Zero is the worst response and 3 is the best response, unless noted
otherwise.
aThe score (range, 1–5) is the number of times the animal turned prone within 2 s when placed in a supine position
out of five tries.
bThe scoring (range, 0 –3) is as follows: 0, does not walk; 1, takes a few steps (less than 8 inches); 2, walks for 9 –18
inches; 3, walks very well beyond 18 inches.
cThe scoring (range, 1–3) is as follows: 0, no increase in tone; 1, slight increase in tone; 2, considerable increase in
tone; 3, limb rigid in flexion or extension.
dGait was graded as 0 (no locomotion), 1 (crawls with trunk touching the ground for few steps and then rolls over),
2 (walks taking alternate steps, trunk low and cannot walk on inclined surface), 3 (walks taking alternate steps,
cannot propel its body using synchronously the hind legs, but walks on 30° inclined surface), 4 (walks, runs, and
jumps without restriction and propels the body using synchronously the back legs, but limitation in speed, balance,
and coordination, manifesting as clumsiness in gait), or 5 (normal walking).
eMotor impairment was defined as weakness in either fore or hind legs and a distance walked of less than 60 inches
in 60 s.
*p  0.05; **p  0.01 (vehicle-treated vs hyaluronidase-treated pups with IVH).
#p  0.05 (glycerol-treated pups without IVH and vehicle-treated pups with IVH).
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TLR4) and formation of HC–HA complexes, but total HA levels
remain unchanged. More importantly, we demonstrated that two
therapeutic strategies enhanced myelination and clinical recov-
ery in rabbits with IVH. First, digestion of HA by ICV hyaluron-
idase treatment reduced CD44 and TLR4 expression, microglia
infiltration, and proinflammatory cytokines, and enhanced my-
elination in rabbits with IVH. Second, ICV HA oligosaccharide
reduced inflammation and enhanced myelination, conceivably
via irreversible HC transfer from pathological HC–HA to the HA
oligosaccharide.
The most important finding of the present study was that
hyaluronidase treatment removed HA from the forebrain and
restored myelination and clinical recovery in preterm rabbits
with IVH. Specifically, we demonstrated that hyaluronidase
treatment (1) reduced microglia infiltration, proinflammatory
cytokine levels, and CD44 and TLR4 expression; (2) reversed
maturational arrest of OPCs, (3) induced transcription of Olig1,
Olig2, and MBP genes favoring myelination; and, thus, (4) pro-
moted myelination and neurological recovery in a developmental
rabbit model of IVH-induced WM injury. Hence, restoration of
OPC maturation after hyaluronidase treatment was seemingly
mediated by two interwoven signaling cascades, including reduc-
tion in levels of HA and CD44 (inflammation independent) and
suppression of inflammation (inflammation dependent). Cell
culture experiments have demonstrated that HA blocks OPC
maturation (Marret et al., 1994; Back et al., 2005), and studies in
an adult rodent model have shown that HMW HA accumulation
in chronic lesions of demyelination inhibits OPC maturation
(Back et al., 2005). Intriguingly, mice engineered to overexpress
CD44 also exhibit inflammation-independent demyelination
(Tuohy et al., 2004). Moreover, our previous study showed that
suppression of inflammation by COX2 inhibition or TNF
downregulation promotes myelination in this animal model
(Vinukonda et al., 2010). Other than in the brain, hyaluronidase
PH20 also inhibits lipopolysaccharide induced neutrophil and
macrophage recruitment in an air pouch model of inflammation
(Huang et al., 2014). These studies reinforce our notion that
hyaluronidase treatment promotes OPC maturation and myeli-
Figure 10. IVH induces TSG-6 activity and synthesis of HC–HA complexes. A, B, Representative Western blot analyses performed on tissues from embryonic WM and GEs of preterm infants with
and without IVH using II specific antibody. Homogenates were digested with hyaluronidase and were run with undigested samples in alternate lanes. The 250, 150, and 85 kDa bands indicate II,
pre-II, and free HCs, respectively. Data are mean  SEM (n  4 each). Note that the HC–HA concentration is higher in GEs of infants with IVH compared to controls without IVH. C, D, Typical
Western blot analyses performed on tissues from WM and GEs of premature infants with and without IVH using II antibody. HA oligosaccharide (10 monosaccharides size) was added to each
homogenate in C. Some homogenates were treated with human recombinant TSG-6 as a positive control. Data are mean  SEM (n  4 each). Note that the HC–HA concentration is higher in GEs
of infants with IVH compared to controls. E, Representative Western blot analyses performed on tissues from GEs of preterm infants with IVH using an I1-specific antibody. Homogenates were
digested with hyaluronidase; treated with HA10, TSG-6, or both TSG and HA10; and incubated for 24 (top) or 72 h (bottom). F, Schematic showing TSG-6-mediated enzymatic transfer of HCs from
II to HA, forming the HC–HA complex (top), and that these HCs can be irreversibly swapped from HC–HA onto HA10. G, Data are shown as mean  SEM (n  5 each). TSG-6 mRNA expressions
were higher in IVH compared to controls at day 3, but not at day 7.
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nation in pups with IVH by both inflammation-dependent and
inflammation-independent mechanisms.
A seminal observation made in this study was an elevation in
TSG-6 expression and an abundance of HC–HA complexes in the
forebrains of subjects with IVH. More importantly, we found that
HA10 treatment to aliquots of fore brain homogenates (autopsy
samples from preterm infants) eliminated HC from pathologi-
cal HC–HA complexes. Although we could not demonstrate
HC–HA complexes in rabbits with IVH in the absence of a suit-
able antibody, HA10 treatment to remove HC suppressed in-
flammation and enhanced myelination as well as neurologic
outcome of pups with IVH. Little is known about the function of
TSG-6 activity and HC–HA complexes. TSG-6 production is in-
duced by proinflammatory mediators including TNF, IL-1,
and prostaglandin E2, and it catalyzes transfer of HCs from inter-
-inhibitor onto HA to form the pathological HC–HA complex
(Milner and Day, 2003). TSG-6 is also considered to exhibit anti-
inflammatory and cytoprotective effects (Watanabe et al., 2013;
Zhang et al., 2013; Kim et al., 2014). However, HC–HA com-
plexes promote inflammation by causing adhesion of HA to the
CD44 on the neutrophil cell surface and increase their extravasa-
tion into the interstitial tissues (Zhuo et al., 2006). An increase in
TSG-6 expression and elevated HC–HA complex have been re-
ported in lung tissues of humans with idiopathic pulmonary hy-
pertension (Lauer et al., 2014) and in the synovial fluid of a
mouse model of rheumatoid arthritis (Lauer et al., 2013b). HA
oligosaccharide treatment has been used in a mouse model of
rheumatoid arthritis to irreversibly remove HC from HC–HA,
thereby reducing joint inflammation (Lauer et al., 2013b). How-
ever, HC–HA complexes have not been evaluated in any devel-
opmental model of hypomyelination or in animal models of
demyelination, and this is the first report to assess the effect of HA
oligosaccharide treatment on cerebral inflammation, myelina-
tion, and neurological outcomes in a developmental model of
brain injury. Hence, elimination of HCs from HC–HA com-
plexes in the survivors of IVH could be a novel strategy to en-
hance myelination of the WM and restore neurological function.
HA oligosaccharides seem to inhibit inflammation and pro-
mote myelination by a number of mechanisms. HA oligosaccha-
rides can interfere with HA–CD44 interactions by inducing
CD44 receptor cleavage or by competitive binding to CD44
(Sugahara et al., 2003; Teriete et al., 2004). However, CD44 ex-
pression was unchanged after HA10 treatment in our model. HA
oligosaccharide (HA12) impairs activated lymphocyte rolling on
Figure 11. Intraventricular injection of an HA10 attenuates inflammation in IVH. A, B, Representative immunofluorescence of Iba1 and CD11b in the corona radiata of day 3 pups, as indicated.
Sytox was used for nuclear staining. Insets show high-magnification views of the boxed areas in the image. Both Iba1  and CD11b  microglia were more abundant in pups with IVH compared to
controls without IVH, and HA10 treatment reduced their density. Scale bars: 50 m. C, TNF and IL1 mRNA expression was elevated in pups with IVH compared to controls with IVH at day 3, and
HA10 treatment reduced their levels. D, HA oligosaccharide treatment suppressed TLR4, but not TLR2 or CD44, at day 3. Data are mean  SEM (n  5 each group). *p  0.05, **p  0.01, ***p 
0.001 (pups with vs without IVH); #p  0.05, ##p  0.01, ###p  0.001 vehicle- vs hyaluronidase-treated pups with IVH.
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CNS endothelial cells, which is independent of CD44 and TLR4
receptors (Winkler et al., 2013). Moreover, HA12 limits demyeli-
nation in a mouse model of experimental autoimmune enceph-
alitis (Winkler et al., 2013). Hence, HA10 oligosaccharide
treatment might be alleviating IVH-induced inflammation by
removing HC from pathological HA, competitive binding of
CD44, and displacing HA from the CD44 receptor.
HA accrues in brain lesions of premature infants with WM
injury, adult stroke, multiple sclerosis, traumatic spinal cord in-
jury, and vanishing WM disease (Back et al., 2005; Struve et al.,
2005; Al’Qteishat et al., 2006; Sloane et al., 2010; Buser et al., 2012;
Cargill et al., 2012). Increased levels of HA have been noted in
CSF of adult patients with vascular dementia, meningoencepha-
litis, spinal stenosis, head injury, cerebral infarction, hydroceph-
alus, and encephalitis (Laurent et al., 1996; Nägga et al., 2014).
Surprisingly, we did not find an increase in HA levels in infants
with IVH, despite large IVH inducing extensive GFAP gliosis in
the periventricular region. Importantly, hyaluronidase treatment
in rabbits with IVH degraded HA into 100 kDa fragments and
alleviated inflammation as well as promoted myelination. Con-
sistent with our study, neither recombinant human PH20 nor its
generated LMW HA fragment stimulated an acute inflammatory
response, but inhibited lipopolysaccharide-induced neutrophil
recruitment in the air pouch model of inflammation (Huang et
al., 2014). In contrast, LMW HA has induced inflammation via
TLR2/4 signaling in a mouse model of lung injury (Noble et al.,
1996). We attribute the differences in the findings between the
studies to differences in the specific size of HA fragment used and
the organ system under study, experimental context, and in vitro
versus in vivo type experiments. It is possible that small HA frag-
ments produced by hyaluronidase treatment might be alleviating
inflammation and promoting myelination, similar to HA10
treatment.
Hyaluronidase treatment in infants with IVH seems promis-
ing. However, this might result in behavioral changes and adverse
effects. HA modulates AMPA receptor mobility, paired-pulse de-
pression, L-type voltage-dependent Ca 2 channel activity, and
long-term potentiation (Kochlamazashvili et al., 2010). It re-
duces contextual fear conditioning and might induce epilepti-
form activity (Vedunova et al., 2013). Since HMW HA inhibits
Figure 12. HA10 treatment restores myelination. A, Typical immunofluorescence of MBP is shown in the corona radiata of day 14 pups. The volume fraction of MBP was elevated in the corpus
callosum and corona radiata of HA10-treated pups compared with vehicle controls. Scale bars: 200 m. V, Ventricle. B, Representative Western blot analysis for MBP on forebrain homogenates of
premature rabbit pups at P14. Adult rat brain was used as a positive control. Each lane represents a lysate from a whole coronal slice taken at the level of the midseptal nucleus. MBP expression was
higher in HA10-treated pups compared with vehicle controls. C, Western blot analysis for MAG in the forebrain of pups at P14. Adult rat brain was used as a positive control. MAG expression was
higher in HA10-treated pups compared with vehicle controls. D, Western blot analysis for CNPase in the forebrain of pups at P14, as indicated. Adult rat brain was used as a positive control. CNPase
expression was higher in HA oligosaccharide-treated pups compared with vehicle controls. E, Typical Western blot analyses for GFAP on the forebrain lysate of rabbit forebrain at P14 are shown. GFAP
expression was comparable between HA10-treated pups and vehicle controls. Bar graphs show the mean  SEM (n  5 each). *p  0.05, **p  0.01, ***p  0.001 (pups with vs without IVH);
#p  0.05, ###p  0.001 (vehicle- vs HA10-treated pups with IVH).
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and LMW HA (3–10 disaccharides) stimulates angiogenesis, hy-
aluronidase treatment might enhance angiogenesis and could
increase the risk of IVH (Slevin et al., 2007). Importantly, intra-
thecal and ICV hyaluronidase have been used in children and
adults with tuberculous meningitis and hydrocephalus in devel-
oping countries, demonstrating clinical efficacy and safety of in-
trathecal hyaluronidase treatment (Gourie-Devi and Satish,
1984; Bhagwati and George, 1986; Gourie-Devi and Satishchan-
dra, 1991). However, the safety and efficacy of ICV hyaluronidase
needs confirmation in infants and children by performing a ran-
domized controlled clinical trial.
In conclusion, the development of IVH in preterm human
infants and rabbit pups did not affect total HA concentration in
the forebrain tissues, but activated HA receptors CD44 and TLR2
as well as TLR4 receptors, thereby inducing microglia infiltration
and elevation in proinflammatory cytokines. There was an asso-
ciated increase in TSG-6 activity and the accumulation of
HC–HA complexes. Two therapeutic interventions— hyaluron-
idase treatment to degrade HA and the removal of HCs from
HC–HA complexes by HA oligosaccharides—reduced inflam-
mation and enhanced OPC maturation, myelination, and neuro-
logical recovery in preterm rabbits with IVH. These treatments
involved ICV injection, which could be traumatic, risky, and
cumbersome for use in human preterm infants. However, con-
sidering the high incidence of neurodevelopmental sequelae in
infants with IVH and more invasive clinical trials performed on
these infants (Whitelaw et al., 2010), intraventricular hyaluroni-
dase might be considered for clinical trial in infants with moder-
ate to severe IVH. Certainly, there is a need for more information
on the adverse effects and pharmacokinetics of these agents. If
treatment with hyaluronidase or HA oligosaccharides demon-
strates efficacy and safety in preventing WM injury in premature
infants, it could improve the neurologic outcome of premature
infants with IVH.
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